The dietary supplement industry is abuzz with a recent development that could significantly impact the way new ingredients are regulated. The U.S. Food and Drug Administration (FDA) has opened a 30-day public comment period, seeking input on four key questions that could redefine what constitutes a 'dietary substance'. This move has sparked intense debate among industry experts, with a clear divide emerging between those advocating for a broader, innovation-forward interpretation and those favoring a more cautious approach. This article delves into the heart of this debate, exploring the implications and potential future directions for the industry.
The Innovation vs. Caution Debate
At the core of the discussion is the interpretation of the phrase 'dietary substance for use by man to supplement the diet by increasing the total dietary intake' within the Dietary Supplement Health and Education Act (DSHEA). Industry stakeholders, including trade associations and independent experts, argue that the current interpretation is too narrow and fails to align with modern science and manufacturing practices. They believe that Congress intended this phrase to be a catch-all innovation category, encompassing substances that have never been part of the conventional food supply.
One of the key figures in this debate is Scott Bass, a principal at Scott Bass Life Sciences LLC and a former architect of DSHEA. Bass provided extensive legislative history, demonstrating that Congress explicitly contemplated ingredients like co-enzyme Q10, glucosamine, probiotics, and synthesized compounds, many of which were not commonly consumed as food. This evidence supports the industry's argument that the 'commonly used as food' test is an unnecessary restriction, contradicting the intent of the New Dietary Ingredient (NDI) provision.
The Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), the Natural Products Association (NPA), and other trade associations echoed this sentiment, emphasizing that Congress separated eligibility from safety, using NDIs and adulteration authority to manage risk. They argue that limiting dietary substances to those already present in the food supply is an outdated approach, especially given the rapid advancements in manufacturing technologies.
The Role of Emerging Technologies
A significant portion of the debate revolves around the use of emerging technologies in producing existing dietary ingredients. Industry stakeholders, including CHPA, CRN, and IPA, argue that the manufacturing method alone should not define the identity or trigger new regulatory status. Instead, they advocate for a product- and risk-based approach, focusing on the finished ingredient's measurable characteristics.
For instance, CRN suggests that regulatory evaluation should consider whether manufacturing changes materially affect identity or safety. When no significant changes occur, companies should have access to efficient mechanisms, such as meetings with the FDA, to confirm continued compliance. This approach ensures that safe, consistent, and high-quality ingredients can be produced using modern techniques without unnecessary regulatory hurdles.
Characterizing Production Technologies
In terms of characterizing production technologies in NDI notifications, industry comments aligned on the need to provide the FDA with comprehensive information to assess safety and identity. This includes a high-level process description, starting materials/inputs relevant to allergens or toxic residues, finished-ingredient specifications, impurity and byproduct profiles, and stability and shelf-life considerations.
AHPA, for instance, emphasizes the importance of consumer transparency regarding source and production method, especially when modern techniques mimic traditional botanicals. They suggest that product labeling should accurately differentiate ingredients produced using traditional and modern methods, ensuring an informed marketplace.
Scientific Criteria for Identity andSameness
The final question addressed by the FDA pertains to scientific criteria for identity and sameness for peptides, proteins, enzymes, and microbials. CHPA outlined specific criteria for identity, including the amino acid sequence or defined mixture profile for peptides/proteins and the catalytic function for enzymes. For microbials, genus/species and strain-level identification are crucial.
IPA, in its comments on microbials, called on the FDA to recognize the shared core characteristics at the species level, while functional benefits and clinical effects are typically strain-specific. They argue that microbial species with a history of safe use in food may qualify under Section 201(ff)(1)(E).
Regarding sameness, commenters suggested that two substances can be considered the same dietary ingredient if they share primary identity, comparable functional attributes within specifications, and no new safety-relevant impurity differences.
The Takeaway
The FDA's public comment period has brought to light a strong consensus among industry stakeholders that dietary supplement ingredients should be eligible for a broad and innovation-forward approach. Safety, they argue, should be rigorous, evidence-based, and enforced through DSHEA's existing tools. This perspective challenges the notion of limiting dietary substances to those already present in the food supply, advocating for a more forward-thinking and inclusive interpretation.
As the industry continues to evolve, the outcome of this debate will significantly impact the regulatory landscape for dietary supplements. The FDA's decision will shape the future of innovation in the industry, influencing the development and introduction of new ingredients that can benefit consumers. The final interpretation of 'dietary substance' will be a pivotal moment, determining whether the industry can fully embrace the potential of modern science and manufacturing while maintaining a robust regulatory framework.
